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Macrophage migration inhibitory factor (MIF) is a mammalian cytokine that participates in innate and
adaptive immune responses. Homologues of mammalian MIF have been discovered in parasite species infect-
ing mammalian hosts (nematodes and malaria parasites), which suggests that the parasites express MIF to
modulate the host immune response upon infection. Here we report the first biochemical and genetic charac-
terization of a PlasmodiumMIF (PMIF). Like human MIF, histidine-tagged purified recombinant PMIF shows
tautomerase and oxidoreductase activities (although the activities are reduced compared to those of histidine-
tagged human MIF) and efficiently inhibits AP-1 activity in human embryonic kidney cells. Furthermore, we
found that Plasmodium berghei MIF is expressed in both a mammalian host and a mosquito vector and that,
in blood stages, it is secreted into the infected erythrocytes and released upon schizont rupture. Mutant P.
berghei parasites lacking PMIF were able to complete the entire life cycle and exhibited no significant changes
in growth characteristics or virulence features during blood stage infection. However, rodent hosts infected
with knockout parasites had significantly higher numbers of circulating reticulocytes. Our results suggest that
PMIF is produced by the parasite to influence host immune responses and the course of anemia upon infection.
Cytokines are the molecular messengers of the vertebrate
immune system, coordinating the local and systemic immune
responses to infective organisms. Macrophage migration inhib-
itory factor (MIF) was one of the first cytokines to be discov-
ered (4, 17) and is involved in both innate and adaptive im-
mune responses. MIF counterregulates the anti-inflammatory
effect of glucocorticoids (9) and is a key regulator of the proin-
flammatory response to endotoxins. For example, MIF-defi-
cient mice survive a lethal dose of lipopolysaccharide (LPS)
(6). MIF is released by immune cells in response to microbial
products and proinflammatory cytokines, such as tumor necro-
sis factor alpha (10, 12). While mammalian MIF is normally
found as a homomeric trimer, each subunit has two catalytic
sites and two activities: a tautomerase activity, which requires
an N-terminal proline residue (33), and an oxidoreductase
activity (29), which is based on a thioredoxin-like motif. Al-
though enzymatic activities are not normally found in cyto-
kines, both of these activities have been linked to MIF’s cyto-
kine function (28, 38, 45). At the molecular level little is known
about the exact mechanisms of MIF function; the biological
substrates for the enzymatic activities of MIF, as well as its
import and export pathways, are not fully understood. So far,
a classical cytokine receptor for MIF has not been discovered,
and the surface receptor (CD74) (32) and the intracellular
factor Jun activation domain binding protein (Jab-1) (27) are
the only functional MIF-binding partners that have been de-
scribed.
Although the mode of action and the complete biological
role of host-derived MIF remain to be established, it has been
shown that MIF also has a critical role in determining the
outcome of infections caused by parasites such as helminths
(42), malaria parasites (34), and Leishmania (44). Interest-
ingly, homologues of human MIF (huMIF) have been charac-
terized in nematodes (39, 48, 49). Parasitic nematodes are long
lived in their hosts and are able to modulate the immune
response to evade killing by the immune system (for a review,
see reference 27). Therefore, it has been suggested that the
expression of MIF homologues plays a role in the immunobi-
ology of and immune evasion by these nematodes. In support
of this, workers have found evidence that nematode MIF has a
role in activating macrophages and in recruitment of eosino-
phils (21). Genome sequencing of other human parasites has
revealed that not only parasitic helminths but also protozoans,
such as Plasmodium, contain genes encoding huMIF homo-
logues (24). Plasmodium is the causative agent of malaria,
which is responsible for over one million deaths annually and
imposes a tremendous social and economic burden (7). The
potential ability of Plasmodium to manipulate the host immune
response though the secretion of cytokine homologues is
clearly of interest.
In this paper we describe the first biochemical and genetic
characterization of the Plasmodium homologues of MIF (PMIF)
from two species, Plasmodium falciparum and Plasmodium
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berghei. We found that C-terminally His6-tagged PMIF exhibits
biochemical and immunostimulatory features similar to those
of huMIF and that it is expressed during the blood stages of
parasite development in a mammalian host. Furthermore, gene
deletion experiments showed that P. berghei MIF (PbMIF) is not
required for completion of the parasite life cycle but signifi-
cantly influences the number of reticulocytes in the circulation
of mice during the early stages of infection. Furthermore, we
found that PMIF is secreted from infected red blood cells and
ruptured schizonts. Coupled with the lack of an essential in-
tracellular function, therefore, our data indicate that PMIF
most likely has a function in the interaction of the parasite with
its host.
MATERIALS AND METHODS
Plasmid construction. To obtain protein expression constructs, MIF reading
frames were amplified from mixed blood stage P. falciparum (PlasmoDB entry
PfMIF: PFL1420w) and P. berghei (GeneDB entry PbMIF: PB000372.03.0)
cDNA by PCR using primers L1632 (5-AAATTTCCGCATGCCGTGCTGTG
AATTAATAAC-3) and L1554 (5-ATTGGATCCACCAAATAGTGAGCCA
CTAAAAGC-3) (underlining indicates restriction sites) for P. berghei and prim-
ers L1667 (5-AAAATTTCCGCATGCCTTGCTGTGAAGTAATAAC-3) and
L1668 5-ATTGGATCCGCCGAAAAGAGAACCACTGAAGGC-3 for P. fal-
ciparum, digested with SphI and BamHI, and ligated into C-terminally His6-
tagged expression vector pQE-70 (QIAGEN). For genomic expression of green
fluorescent protein (GFP)-tagged PbMIF, the MIF gene and promoter region
(1,200-bp upstream sequence) were amplified from P. berghei genomic DNA
using primers L1879 (5-AAAGGTATTCCATGGAACCAAATAGTGAGCCA
CTAAAAGCA-3) and L1880 (5-TAAATCAAAGCGGCCGCGAATCTTAT
CAACCATTTATACC-3), digested with NcoI and NotI, and ligated into the
C-terminally GFP-tagged integration construct pGFP-TAG (30) or pMYC-
TAG, which was generated by transferring the c-myc tag from pSD141 (41), a
kind gift from Oliver Billker (Imperial College, London, United Kingdon), into
pGFP-TAG using primers L2300 (5-CGGGGTACCGCGGCCGCTATCTAG
ACGAGGATCCATGGGGCCCGAACAAAAACTCATC-3) and L2301 (5-G
AGCAGATTGTACTGAGAGTGCACCATATGCGGTG-3). To obtain a
MIF knockout vector, an upstream region (positions 1200 to 300) and a
downstream region (positions 785 to 1700) from the pbmif gene were amplified
from P. berghei genomic DNA using primers L1466 (5-TAAATCAAGGTACC
GGCGAATCTTATCAACCATTTATACC-3) and L1467 (5-TTGTATTTCA
TCGATCTCTTGTGATATTAATCCATACACGCC-3) and primers L1468 (5-
AAAGAGGCTGAATTCTATGTAAATTATTTTTCCTATGCCCTTAAC-3) and
L1469 (5-ATCGGATCCTTATGCGTATATATATTGAAGCATGGTG-3),
respectively. The PCR products were digested with Asp718 plus ClaI and EcoRI
plus BamHI, respectively, and ligated into B3D (46). All constructs were se-
quenced to confirm MIF sequence identity.
Protein purification and refolding. P. falciparum MIF (PfMIF) and PbMIF
were expressed in BL21(DE3)(pLysS) bacteria grown on Luria broth (Q-bio-
gene) containing 30 g/ml chloramphenicol and 0.05 g/ml ampicillin. Bacteria
were grown at 37°C to an optical density at 600 nm of 0.4 and were induced by
addition of isopropyl-D-thiogalactoside to a final concentration of 1 mM. After
3 h, the cells were harvested and lysed in 50 mM Tris (pH 8.0), 500 mM NaCl,
10% (vol/vol) glycerol, 0.01% Nonidet P-40, 10 mM -mercaptoethanol in the
presence of complete protease inhibitor cocktail (Roche) and 1 g/ml lysozyme.
Genomic DNA was fragmented by sonication, after which the lysate was cleared
by centrifugation at 30,000  g for 45 min at 4°C and loaded onto an Ni-
nitrilotriacetic acid column (QIAGEN) equilibrated in 50 mM Tris (pH 8.0), 200
mM NaCl, 10% (vol/vol) glycerol, 20 mM imidazole, 10 mM -mercaptoethanol.
After washing, the protein was eluted in a linear 20 to 400 mM imidazole
gradient. Peak fractions were pooled, concentrated to 10 ml in an Amicon stirred
ultrafiltration cell (Millipore) using a 10-kDa-cutoff filter, and loaded on a
Superdex 75 gel filtration column (Amersham Pharmacia) equilibrated in 50 mM
Tris (pH 8.0), 200 mM NaCl, 5% (vol/vol) glycerol, 5 mM -mercaptoethanol.
These preparations and MIF preparations of refolded lyophilized recombinant
MIF (3) were confirmed to be free of LPS (5 ng of LPS/mg of protein) by the
Limulus amoebocyte assay (Biowhittaker Inc., Walkersville, MD).
Oxidoreductase and tautomerase assays. Oxidoreductase and tautomerase
assays were performed as described previously (29, 43), except that 1H nuclear
magnetic resonance spectra during the tautomerase analysis were recorded with
1-min intervals using a Bruker DPX-300 with 3-(trimethylsilyl)tetradeutero-
propionic acid sodium salt as the internal standard.
Antibody generation and Western blotting. Polyclonal antibodies against
PbMIF were raised in New Zealand White rabbits by injecting 100 g LPS-free
PbMIF linked to keyhole limpet hemocyanin in complete Freund’s adjuvant.
After three boosts with 100 g keyhole limpet hemocyanin-linked PbMIF in
incomplete Freund’s adjuvant, 5 ml of serum was collected and used at a 1/1,000
dilution as the primary antibody for Western blotting.
Immunofluorescence assays. Blood stages from overnight schizont cultures
were fixed with paraformaldehyde, and the c-myc tag was visualized by incubation
with anti c-myc monoclonal antibody (C3956; Sigma-Aldrich, The Netherlands),
followed by staining with fluorescein isothiocyanate-labeled goat anti-rabbit im-
munoglobulin G antibody. Parasite nuclei were stained using 4,6-diamidino-2-
phenylindole (DAPI) (Sigma-Aldrich, The Netherlands) according to the man-
ufacturer’s instructions. Fluorescence was visualized using fluorescence MDR
microscopy (GFP and DAPI filter settings; Leica), and images were recorded
using a DC500 digital camera.
AP-1 activation assay. The AP-1 assay was performed as described previously
(26, 28). Briefly, 1.7  105 human embryonic kidney (HEK) cells per well were
plated in 24-well cell culture plates. After 24 h, transfection with 50 ng pAP-1-
luciferase reporter plasmid and 1 ng pRenilla control plasmid (dual-luciferase
reporter assay system; Promega, Leiden, The Netherlands) per 1.7  105 HEK
cells was performed using lipofectamine 2000 (Invitrogen) as the transfection
reagent. Cells were allowed to recover from transfection for 18 h. Then trans-
fected cells were preincubated with recombinant human MIF or PMIF or with
control buffer for 1 h, followed by an 8-h coincubation with 3 nM phorbol
myristate 13-acetate (PMA). Both the PMA concentration and the incubation
time were optimized in pilot experiments to obtain the greatest induction of the
AP-1 promoter without causing significant cell death. Control cells (basal) were
not incubated with PMA. Cells were washed, and cell lysates were prepared using
100 l passive lysis buffer (dual-luciferase reporter assay system; Promega) to
quantify luciferase and renilla activities according to the protocol of the manu-
facturer.
Gene knockout and tagging in P. berghei. Transfection and selection of para-
sites with pbmif deleted or of tagged parasites were performed as previously
described (18). Genomic integration of knockout and tagging vector DNA was
confirmed by Southern blotting of pulse-field gel electrophoresis-separated chro-
mosomes of the knockout or tagged parasites and probing with the 3 untrans-
lated region of the PbDHFR gene. In addition, correct replacement of the
PbMIF locus was verified by Southern blotting of AccI- and AccI/XbaI-digested
wild-type and pbmif knockout (pbmif-ko) parasite genomic DNA and probing
with the upstream pbmif knockout target region (positions 1200 to 300). The
pbmif-ko lines and the line expressing c-myc-tagged PbMIF were cloned using
limiting dilution, whereas the line expressing GFP-tagged PbMIF was not cloned
using limiting dilution.
Virulence experiments. In two experiments, five hosts (mouse strains BALB/c
and C57BL/6) were infected with HP-ANKA wild-type P. berghei parasites and
five hosts were infected with pbmif-ko parasites (pbmif-ko1). In addition, in the
second experiment, five hosts for both mouse strains were also infected with a
second independently generated pbmif-ko parasite line (pbmif-ko2). All parasite
lines were generated from the same stock (passage number). All mice (Haarlan,
United Kingdom) were randomized into groups with respect to weight and red
blood cell count, infected intraperitoneally with 1  105 ring stage parasites, and
monitored daily from day 3 postinfection. Every day of sampling, mice were
weighed, thin smears were prepared, and the red blood cell densities were
calculated by flow cytometry (the mature red blood cells and reticulocytes in the
size range from 3.3 to 10 m in diameter in 2 l of tail blood were counted
according to the manufacturer’s instructions; Coulter Electronics, United King-
dom). Mice were sampled until the level of parasitemia became very high
(50%) and/or substantial mortality occurred (day 12 postinfection for BALB/c
hosts and day 7 postinfection for C57BL/6 hosts).
Analysis of virulence experiments. The proportion of parasitized red cells
(parasitemia) and the proportion of red cells that were reticulocytes (reticulo-
cytemia) were calculated daily from thin smears, and the results were trans-
formed to obtain parasite and reticulocyte densities using red cell density counts.
The following summary statistics for each infected host were calculated: cumu-
lative densities for parasites and reticulocytes; red cell and mass loss; minimum
red cell density and mass; and peak parasitemia and reticulocytemia. Proportion
data were arcsin square root transformed to comply with the assumptions of
parametric tests. For all experiments, general linear models (R Foundation for
Statistical Computing, Austria) were used to compare infection parameters for
pbmif-ko and wild-type infections, and Tukey tests were used to determine which
groups differed when significant results were obtained.
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RESULTS
MIF is expressed constitutively by Plasmodium and secreted
by blood stage forms. MIF homologues have been found pre-
viously in a number of parasitic nematodes (21, 48, 49) and
have now also been found in apicomplexans, including Plas-
modium (PlasmoDB entry PfMIF: PFL1420w; GeneDB entry
PbMIF: PB000372.03.0). These parasite MIFs exhibit moder-
ate levels of homology with mammalian MIFs and with each
other (29% identity and 39% similarity between huMIF and
PfMIF) (Fig. 1A). Nevertheless, a crystal structure determina-
tion of nematode MIF protein revealed that the overall struc-
ture of the divergent MIF proteins is highly conserved (45),
and thus the sequence of parasite MIFs can be accurately
threaded onto the human MIF structure. Conserved residues,
shown in Fig. 1B in ball-and-stick form in the crystal structure
of huMIF (33), mainly cluster around the tautomerase active
site (residues 2, 32 to 34, and 64 to 66), indicating that the
tautomerase activity is likely to be a shared property of mam-
malian and parasite MIFs. In contrast, the second cysteine in
the mammalian MIF CXXC oxidoreductase motif does not
seem to be as well conserved in the parasite MIFs (Fig. 1A).
To determine the expression profile of PbMIF, we analyzed
P. berghei infection at various stages by Northern blotting.
pbmif was transcribed throughout the asexual blood stages, and
peak steady-state mRNA levels were observed at the late tro-
phozoite and early schizont stages (Fig. 2A). Furthermore, we
FIG. 1. Sequence alignment of mammalian and parasite MIFs. (A) Sequence alignment of human, mouse, P. berghei (Pb), and P. falciparum
(Pf) MIF homologues, as well as two Brugia malayi MIF homologues (Bm-1 and -2). The arrow indicates the N-terminal catalytic proline associated
with tautomerase activity, and the area enclosed in a box is the CXXC motif associated with oxidoreductase activity in the mammalian MIFs and
the parasite variants. Asterisks indicate identical residues; colons and dots indicate residues with high and low levels of similarity, respectively.
(B) Ribbon representation of the huMIF crystal structure (RCSB PDB entry: 1CA7 [33]). For clarity, only one monomer of the trimer is shown.
Arrows indicate the positions of the tautomerase and oxidoreductase active sites. The first cysteine of the CXXC oxidoreductase motif (C57 in
huMIF) that is conserved in the parasite MIFs is red. Conserved residues in the various MIFs mainly cluster around the tautomerase active site
and are shown in ball-and-stick form.
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tracked PbMIF protein expression by examining generation of
a knockin P. berghei strain expressing C-terminally GFP-tagged
PbMIF under control of the endogenous promoter (Fig. 3B).
Since the molecular weight of the GFP tag is about three times
the molecular weight of the PbMIF monomer, the presence of
GFP may affect the cellular distribution of PbMIF. Therefore,
we did not draw any conclusion with regard to cellular local-
ization of the fusion, other than presence or absence at a given
stage of the life cycle. PbMIF-GFP was found to be expressed
ubiquitously in the blood stages and in mosquito stage ooki-
netes and sporozoites (Fig. 2B to I).
Any function of PMIF in a parasite-host interaction or in
immune evasion would require PMIF to be externalized by the
parasite. However, like mammalian MIF, which is exported by
nonclassical pathways likely involving an ABCA1 transporter
(22), PMIF has no signal sequence. To analyze whether PMIF
is released from parasite-infected erythrocytes, we developed a
polyclonal antibody specific for PbMIF and immunoblotted
supernatants and lysates of synchronous, cultured P. berghei
blood stage parasites. This antibody showed extremely low
cross-reactivity with recombinant huMIF during a long expo-
sure (5 min) of the blot (Fig. 4A, lanes 12 and 13), which is
virtually identical to the results obtained with murine MIF
(89% identity and 95% homology). Nevertheless, to prevent
any confounding presence of murine MIF, we removed all
leukocytes by passing the sample over a Plasmodipur filter
(Euro-Diagnostica, Arnhem, The Netherlands). When grown
in culture, P. berghei blood stage parasites arrest in the late
schizont stage, since the infected erythrocytes do not rupture
(47). This allows workers to discriminate between active secre-
tion throughout asexual growth and release by the infected
erythrocyte at the time of schizont rupture. Figure 4A shows
that significant levels of PbMIF were present in the cytoplasm
of the infected erythrocytes in both the trophozoite and schi-
zont stages. A small quantity of PbMIF was also detected in
the culture supernatant, but the amount varied between
experiments (not shown), so the MIF was likely released by
mechanical shearing of infected erythrocytes. Mechanical
rupture of the parasitophorous vacuole of the schizonts,
releasing the merozoites, resulted in release of an additional
burst of PbMIF. Lysis of trophozoites or merozoites released
additional MIF.
Rabbit polyclonal PbMIF antisera showed high nonspecific
cross-reactivity in an immunofluorescence assay, precluding
direct visualization of PbMIF in infected cells. Therefore, a
knockin P. berghei strain expressing PbMIF with the much
smaller (2.7-kDa) C-terminal c-myc tag (Fig. 3B) was gener-
ated, enabling direct detection of the fusion using monoclonal
anti-c-myc antibodies. Figure 4B1 shows staining of the para-
sitophorous vacuole in trophozoites and schizonts, along with
faint staining of the infected erythrocyte cytoplasm in the tro-
phozoite. Schizont rupture resulted in a loss of fluorescence
(Fig. 4B2), consistent with the results shown in Fig. 4A.
Expression and purification of recombinant PMIF-His6 and
measurement of enzymatic activities. Although all MIFs are
structurally conserved, the conservation of the residues asso-
ciated with the two known enzymatic activities is greater for
the tautomerase activity than for the oxidoreductase activity.
Since the N-terminal proline is the catalytic residue in the
tautomerase activity (33) and we wanted to compare the en-
zymatic properties of PMIF with those of huMIF, we located
the His6 tag at the C terminus well away from any enzymatic
site in our PbMIF, PfMIF, and huMIF expression constructs.
The major peak of PMIF-His6 eluted at an apparent molecular
mass of 30 kDa on a size exclusion column, while huMIF-His6
eluted at an apparent molecular mass of 22 kDa. Both values
are consistent with a dimeric form in solution (Fig. 5A). We
determined the tautomerase activity of the purified recombi-
nant PMIF-His6 by monitoring the conversion of p-hydroxy-
FIG. 2. Expression of PbMIF throughout the life cycle. (A) Time
course Northern analysis of the PbMIF transcript in blood stages.
Whole RNA extracted at various times from a synchronous P. berghei
blood stage infection showed that there was production of PbMIF
mRNA of the expected size (	0.7 kb) at 17 h postinfection (HPI)
(trophozoite stage). Small quantities of transcript were also present in
the sexual stages (Gct 1, enriched gametocytes; Gct 2, purified game-
tocytes) and the ookinete (Ook). An ethidium bromide-stained portion
of the gel showing the positons of the 28S and 18S rRNAs was included
as loading control. (B to E) Protein expression of the PbMIF-GFP
fusion throughout the life cycle in a late ring/early trophozoite (B),
mature trophozoite (C), schizont (D), and mature ookinete (some
unfertilized female gametes are also visible) (E). Magnification, 100.
(F and G) Protein expression of the PbMIF-GFP fusion in a day 18
oocyst. Magnification, 20 and 40, respectively. (H and I) Protein
expression of the PbMIF-GFP fusion in salivary gland sporozoites.
Magnification, 40 and 100, respectively. Bars, 10 m.
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phenylpyruvate from the enol form to the keto form by 1H
nuclear magnetic resonance (43). PfMIF-His6 and PbMIF-His6
showed levels of tautomerase activity that were appreciably
above the background level of the mock purification control,
but the activity was fivefold lower that the activity of wild-
type huMIF-His6, which was used as a control (Fig. 5B). We
next tested whether PMIF-His6 exhibited oxidoreductase
activity and quantified the NADPH-dependent reduction of
2-hydroxyethyldisulfide (HED). Figure 5C shows that the
oxidoreductase activity of PfMIF-His6 was able to catalyze
the reduction of HED at levels greater than the levels ob-
served for the mock purification control. Surprisingly, given
the lack of conservation, the oxidoreductase activity was also
reduced only about fivefold compared to the activity of the
huMIF-His6 wild-type control. In both assays, PbMIF-His6
exhibited less activity than PfMIF-His6 exhibited. Given the
high level of conservation between these two MIFs, how-
ever, this was unlikely to be due to lower intrinsic activity
FIG. 3. Genetic manipulation of the pbmif locus. (A) pbmif-ko was made by double-crossover replacement using the 5 untranslated region
(5UTR) (positions 1200 to 300) and 3 untranslated region (3UTR) (positions 785 to 1700) from the pbmif gene. Gene replacement with the
TgDHFR/TS selection marker removed the XbaI site in the 3 untranslated region of PbMIF and introduced an additional AccI site. The sizes
of restriction fragments are indicated between arrows, and the hatched box represents the region that was used as a probe in the Southern analysis
whose results are shown in panel C. (B) PbMIF-GFP and c-myc fusions were made by a single-crossover knockin (insertion) event, which resulted
in gene duplication of pbmif with one of the two copies tagged with GFP or c-myc, while the second copy remained wild type. (C) Southern blot
analysis of AccI- and AccI/XbaI-digested genomic DNA from wild-type and knockout parasites. Using the 5 untranslated region integration target
(hatched box in panel A) as the probe, the digestions should have yielded 2,447-, 2,100-, 2,616-, and 2,616-bp fragments, respectively.
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but rather may have reflected small differences in refolding
efficiency.
Recombinant PMIF is as efficient as huMIF in inhibiting
AP-1 stimulation. We investigated if the in vivo activity of
PMIF-His6 mirrored the reduced enzymatic activity of PMIF-
His6 compared to huMIF-His6 activity. huMIF can reduce
AP-1 expression by physically interacting with the transcrip-
tional coactivator Jab-1, an activity at least partially dependent
on the oxidoreductase activity of huMIF (28). Therefore, we
used an AP-1 reporter assay with HEK cells to examine the
biological activity of recombinant PMIF-His6. Figure 6 shows
that although both huMIF-His6 and PMIF-His6 showed a
trend toward repression of the basal expression of AP-1, this
effect became statistically relevant (P  0.05; n  6) only after
AP-1 expression was induced with PMA. The induction of the
AP-1 promoter by PMA was quite subtle in HEK cells. Higher
levels of induction could be obtained by increasing the PMA
concentration and incubation time, but they were invariably
associated with increased cell death. Nevertheless, the repres-
sion effect was on the same order of magnitude for both hu-
MIF-His6 and PMIF-His6, which implies that PMIF is able to
bind to and interfere with Jab-1 to the same extent as huMIF
despite its reduced oxidoreductase activity.
PbMIF knockout parasites are viable throughout the life
cycle and increase host reticulocyte density. To investigate the
role of PbMIF during in vivo infection in the mouse host and
mosquito vector, two independent pbmif-ko parasite lines were
generated using double-crossover gene replacement. Correct
integration of the selection marker and disruption of the pbmif
locus were confirmed by pulse-field gel electrophoresis, PCR
(not shown), and Southern blotting (Fig. 3). pbmif-ko parasites
were viable in vivo, replicated asexually at the same rate as
FIG. 4. PbMIF is externalized by P. berghei and is released upon
schizont rupture. (A) Western blot analysis using anti-PbMIF rabbit
polyclonal antiserum. Lane 1 contained erythrocytes (ery.) infected
with trophozoite (troph.) stage P. berghei that were isolated by heart
puncture and lysed by osmotic shock. Parasite-derived MIF was pulled
down from the lysis supernatant (sup.) (from the equivalent of 107
infected erythrocytes) using anti-PbMIF bound to protein G-Sepha-
rose. Lane 2 contained control pulldown of the lysis supernatant using
protein G-Sepharose alone. Lane 3 contained a trophozoite pellet
(	2.0  105 parasites loaded). Lane 4 contained control pulldown of
100 ng of recombinant (rec.) C-terminally His6-tagged PbMIF using
protein G-Sepharose alone. Lane 5 contained control pulldown of 100
ng of recombinant C-terminally His6-tagged PbMIF using anti-PbMIF
loaded protein G-Sepharose. Lane 6 contained supernatant (10 l of
100 ml) of an overnight schizont (schiz.) culture. Lane 7 contained
supernatant (10 l of 20 ml) of schizonts after disruption of the host
erythrocyte membrane. Lane 8 contained phosphate-buffered saline
wash supernatant (10 l of 1 ml) of schizont pellet from lane 7. Lane
9 contained supernatant (10 l of 1 ml) after mechanical rupturing of
the schizonts into merozoites. Lane 10 contained phosphate-buffered
saline wash supernatant (10 l of 1 ml) of the merozoites from lane 9.
Lane 11 contained solubilized merozoite pellet (	2.0  105 parasites
loaded). Lane 12 contained 50 ng of recombinant C-terminally His6-
tagged PbMIF. Lane 13 contained 100 ng of recombinant huMIF. (B)
Immunofluorescent detection of c-myc-tagged PbMIF in blood stages.
Thin smears from an overnight schizont culture expressing PbMIF–c-
myc were stained using an anti-c-myc monoclonal antibody. (Panel 1)
Intact schizont and trophozoite (arrowhead) show staining within the
parasitophorous vacuole. (Panel 2) Intact schizont and ruptured schi-
zont. (Panel 3) Wild-type P. berghei control stained with the anti-c-myc
monoclonal antibody. The fluorescent image in panel 3 was taken
with a 0.6-s exposure, while the fluorescent images in panels 1 and 2
were taken with a 0.3-s exposure. Bars, 10 m. FITC, fluorescein
isothiocyanate.
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wild-type parasites, formed sexual stage parasites at the wild-
type frequency, and were transmitted throughout the full life
cycle (not shown). Since PbMIF may have a more subtle role in
parasite-host interactions, we investigated pbmif-ko parasite
FIG. 5. Recombinant PMIF elutes as a dimer in size exclusion
chromatography and is active in tautomerase and oxidoreductase as-
says. (A) Chromatograms of C-terminally His6-tagged huMIF and
PbMIF. The retention volume of the major peak for C-terminally
His6-tagged PbMIF was 192.10 ml, compared to 204.87 ml for C-
terminally His6-tagged huMIF, which resulted in calculated molecular
masses of 30 kDa for PbMIF and 22 kDa for huMIF. The reference
compounds included bovine albumin (66 kDa; 153.93 ml), chicken
ovalbumin (45 kDa; 170.93 ml), bovine carbonic anhydrase (30 kDa;
192.47 ml), and bovine 
-lactalbumin (14.4 kDa; 217.39 ml). The inset
shows a Coomassie blue-stained protein gel containing the peak frac-
tions for PbMIF, which identified the void volume peak as PbMIF
aggregates. The same results were obtained with PfMIF (data not
shown). mAU, milli-absorbance units. (B and C) Recombinant MIF
tautomerase activity with p-hydroxyphenylpyruvate (R  COOH and
R  C6H4-OH) (B) and oxidoreductase activity with 2-hydroxyethyl-
disulfide (R  CH2-OH) (C). Sample equations are shown for both
conversions. The activities of PfMIF and PbMIF are expressed as
percentages of the huMIF activity. In both sets of experiments, the
PfMIF and PbMIF activities were greater than the activities of the
mock purification control. Asterisks indicate that the P value is 0.05
(n  3).
FIG. 6. Recombinant PMIF can inhibit AP-1 induction like hu-
MIF. At the basal level of transcription, both huMIF and PMIF
showed a nonsignificant trend toward inhibition of AP-1 transcription
in HEK cells. However, upon stimulation with PMA, both huMIF and
PMIF showed statistically relevant repression compared to buffer con-
trols. Asterisks indicate that the P value is 0.05 (n  6).
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virulence and infection dynamics in two inbred mouse strains,
BALB/c and C57BL/6.
In C57BL/6 mice, P. berghei ANKA infection (intraperito-
neal injection of 1  105 parasites) generally leads to cerebral
complications, presenting as ataxia, shivering, lethargy, and
death at days 8 to 9 after infection as the level of parasitemia
reaches 	10% (16, 20). P. berghei ANKA infection in BALB/c
mice may lead to similar cerebral complications in a small
proportion of mice or, more commonly, to a syndrome termed
severe malaria (19, 20), in which mice suffer from severe ane-
mia, weight loss, and organ damage from day 8 after infection
that are associated with a high level of parasitemia. Mice in-
fected with wild-type or pbmif-ko parasites had symptoms con-
sistent with these syndromes; infection of C57BL/6 mice re-
sulted in death at day 8 postinfection, and infection of BALB/c
mice resulted in high levels of parasitemia and severe anemia
(Tables 1 and 2) in all cases.
In both experiments, with two independently generated
pbmif-ko lines and two mouse strains, hosts infected with the
pbmif-ko lines had significantly higher reticulocyte densities
and peak levels of reticulocytemia than hosts infected with
wild-type parasites (Fig. 7; Tables 1 and 2). In contrast, none of
the other virulence parameters revealed consistently significant
differences between infections with pbmif-ko parasites and in-
fections with wild-type parasites. In both experiments, infec-
tions with the first pbmif-ko line (pbmif-ko1) did not differ
significantly from infections with wild-type parasites in terms of
cumulative parasite density, peak parasitemia, minimum mass,
mass loss, minimum red cell density, or red cell loss. When
infections initiated with the second pbmif-ko line (pbmif-ko2)
were compared to infections with wild-type parasites, there
were no significant differences in peak parasitemia, minimum
mass, mass loss, or red cell loss. However, compared to infec-
tions with wild-type parasites, for infections with pbmif-ko2
parasites the cumulative parasite densities were significantly
higher, but only in BALB/c mice, and the minimum red cell
TABLE 1. Comparison of virulence parameters for infections with wild-type and pbmif-ko parasitesa
Host mice Variable Test statistics Further details
BALB/c Cumulative parasite density F(1,8)  0.59; P  0.464 Wild type infections: 1.04  0.15
pbmif-ko1 infections: 0.68  0.16
Peak parasitemia F(1,8)  5.00; P  0.056 Wild type infections: 7.24  1.03
pbmif-ko1 infections: 4.88  1.20
Minimum mass F(1,8)  3.04; P  0.119 Wild type infections: 17.74  0.53
pbmif-ko1 infections: 18.38  0.19
Minimum red blood cell density F(1,8)  0.20; P  0.668 Wild type infections: 8.00  0.29
pbmif-ko1 infections: 8.29  0.22
Cumulative reticulocyte density F(1,8)  44.0; P < 0.001 Wild-type-infected hosts had significantly fewer reticulocytes (0.18 
0.02) than pbmif-ko1-infected hosts (0.79  0.10)
Peak reticulocytemia F(1,8)  48.6; P < 0.001 Wild-type-infected hosts had significantly lower peak reticulocytemia
(1.02  0.07) than pbmif-ko1-infected hosts (3.32  0.45)
C57BL/6 Cumulative parasite density F(1,7)  2.63; P  0.149 Wild type infections: 2.14  0.22
pbmif-ko1 infections: 1.72  0.15
Peak parasitemia F(1,7)  3.86; P  0.091 Wild type infections: 14.83  1.78
pbmif-ko1 infections: 11.18  1.02
Minimum mass F(1,7)  2.75; P  0.142 Wild type infections: 17.07  0.44
pbmif-ko1 infections: 18.56  0.71
Minimum red blood cell density F(1,7)  1.26; P  0.299 Wild type infections: 6.93  0.46
pbmif-ko1 infections: 7.58  0.37
Cumulative reticulocyte density F(1,7)  8.74; P  0.021 Wild-type-infected hosts had significantly fewer reticulocytes (1.31 
0.14) than pbmif-ko1-infected hosts (1.90  0.15)
Peak reticulocytemia F(1,7)  5.57; P  0.0503 There was a borderline trend for the peak reticulocytemia of wild-type-
infected hosts (10.4  0.84) to be marginally higher than the peak
reticulocytemia of pbmif-ko1-infected hosts (8.12  0.63). However,
the mean reticulocytemia was higher in pbmif-ko1-infected hosts on
3 of the 4 days examined. Therefore, this trend does not contradict
the reticulocyte density results.
a Results of experiment 1, in which BALB/c hosts and C57BL/6 hosts were infected with either wild-type or pbmif-ko1 parasites. The statistics are from general linear
models, and the F ratio represents the variance attributable to each explanatory variable when the variance remaining unexplained by the model was compared. This
ratio was weighted by the degrees of freedom associated with each explanatory variable and compared to the appropriate F distribution to generate the P value. For
all variables, means and standard errors are shown. Variables for which wild-type infections differed significantly from pbmif-ko infections are indicated by boldface,
and further explanation is provided. The units are percentages for proportion data and 109 cells/ml for density data.
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TABLE 2. Comparison of virulence parameters for infections with wild-type and two independently generated pbmif-ko parasitesa
Host mice Variable Test statistics Further details
BALB/c Cumulative parasite density F(2,12)  8.32; P  0.005 Wild-type parasites (0.13  0.04) did not reach significantly different
densities than pbmif-ko1 parasites (0.28  0.09), but pbmif-ko2
parasites (0.76  0.16) reached significantly higher densities than
both other genotypes. The data do not show a consistent trend for
pbmif-ko parasites to reach higher densities than wild-type
parasites.
Peak parasitemia F(2,12)  0.06; P  0.946 Wild type infections: 12.90  2.32
pbmif-ko1 infections: 9.61  2.14
pbmif-ko2 infections: 11.74  2.59
Minimum mass F(2,12)  0.44; P  0.653 Wild type infections: 17.57  0.38
pbmif-ko1 infections: 17.05  0.44
pbmif-ko2 infections: 16.73  0.87
Mass loss F(2,12)  0.11; P  0.901 Wild type infections: 3.33  0.52
pbmif-ko1 infections: 3.08  0.84
pbmif-ko2 infections: 2.87  0.67
Minimum red blood cell density F(2,12)  0.18; P  0.835 Wild type infections: 5.07  0.43
pbmif-ko1 infections: 5.04  0.23
pbmif-ko2 infections: 4.79  0.39
Red blood cell loss F(2,12)  0.14; P  0.871 Wild type infections: 5.21  0.84
pbmif-ko1 infections: 4.91  0.29
pbmif-ko2 infections: 5.36  0.54
Cumulative reticulocyte density F(2,12)  17.69; P < 0.001 Wild-type-infected hosts had significantly fewer reticulocytes (1.13 
0.07) than pbmif-ko1-infected hosts (2.51  0.25) and pbmif-ko2-
infected hosts (2.28  0.15)
Peak reticulocytemia F(2,12)  24.00; P < 0.001 Wild-type-infected hosts had significantly lower peak levels of
reticulocytes (2.10  0.22) than pbmif-ko1-infected hosts (4.24 
0.35) and pbmif-ko2-infected hosts (5.56  0.57)
C57BL/6 Cumulative parasite density F(2,12)  0.95; P  0.415 Wild type infections: 0.67  0.15
pbmif-ko1 infections: 0.50  0.10
pbmif-ko2 infections:0.79  0.19
Peak parasitemia F(2,12)  1.93; P  0.188 Wild type infections: 6.48  1.54
pbmif-ko1 infections: 5.18  1.27
pbmif-ko2 infections: 10.36  2.70
Minimum mass F(2,12)  1.97; P  0.182 Wild type infections: 16.42  0.42
pbmif-ko1 infections: 16.53  0.46
pbmif-ko2 infections: 16.41  0.30
Mass loss F(2,12)  0.03; P  0.975 Wild type infections: 0.34  0.17
pbmif-ko1 infections: 0.82  0.15
pbmif-ko2 infections: 0.94  0.32
Minimum red blood cell density F(2,12)  11.84; P  0.001 pbmif-ko2-infected hosts were more anemic (4.74  0.29) than wild-
type-infected hosts (7.27  0.35). pbmif-ko1-infected hosts (5.86 
0.43) did not have significantly different minimum red cell
densities than wild-type-infected hosts. Therefore, there was not a
consistent trend for pbmif-ko-infected hosts to be less anemic than
wild-type-infected hosts.
Red blood cell loss F(2,12)  2.28; P  0.102 Wild type infections: 2.33  0.20
pbmif-ko1 infections: 2.75  0.84
pbmif-ko2 infections: 4.15  0.48
Cumulative reticulocyte density F(2,12)  8.61; P  0.005 Wild-type-infected hosts had significantly fewer reticulocytes (0.41 
0.10) than pbmif-ko1-infected hosts (1.57  0.30) and pbmif-ko2-
infected hosts (1.36  0.18)
Peak reticulocytemia F(2,12)  7.93; P  0.006 Wild-type-infected hosts had significantly lower peak levels of
reticulocytes (2.20  0.58) than pbmif-ko1-infected hosts (10.07 
2.35) and pbmif-ko2-infected hosts (9.23  1.77)
a Results of experiment 2, in which in which BALB/c hosts and C57BL/6 hosts were infected with either wild-type parasites or one of two independent lines of
pbmif-ko parasites (pbmif-ko1 and pbmif-ko2). The statistics are from general linear models, and the F ratio represents the variance attributable to each explanatory
variable when the variance remaining unexplained by the model was compared. This ratio was weighted by the degrees of freedom associated with each explanatory
variable and compared to the appropriate F distribution to generate the P value. For all variables, means and standard errors are shown. Variables for which wild-type
infections differed significantly from pbmif-ko infections are indicated by boldface, and further explanation is provided. The units are percentages for proportion data
and 109 cells/ml for density data.
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densities were significantly lower, but only in C57BL/6 mice.
Therefore, only reticulocyte parameters differed consistently
and significantly between infections with both pbmif-ko lines
and wild-type infections in BALB/c and C57BL/6 mice (Fig. 7;
Tables 1 and 2).
DISCUSSION
It is now clear that the cytokine MIF is an evolutionarily
ancient protein with a widespread distribution. MIF homo-
logues in parasitic nematodes have been functionally charac-
terized (21, 49). Furthermore, genome-sequencing projects
have shown that MIF homologues are present in the protozoan
parasites Toxoplasma gondii and Leishmania major, but genes
encoding MIF are absent from the published genomes of other
protozoans, including the related apicomplexan parasites Cryp-
tosporidium parvum, Theileria parvum, and Theileria annulata,
and free-living eukaryotes, including Dictyostelium discoideum
and the ciliate Tetrahymena thermophila. Thus, at present the
expression of MIF homologues in unicellular eukaryotes is
consistently associated with a group of parasitic protozoans
that engage in specialized interactions with host cells in blood.
Here we describe our initial functional characterization of the
Plasmodium MIF homologue. The use of the term “homo-
logue” instead of “orthologue” in the case of the parasite-
derived MIF is justified, since while we show that there is
conservation in function, we cannot at this time rule out addi-
tional properties of parasite-derived MIF that are not shared
with host MIF.
While PbMIF transcription appears to peak at the tropho-
zoite stage in asexual blood stage parasites, PbMIF is ex-
pressed in all parasite forms examined throughout the life cycle
and is distributed in the cytoplasm of both the parasite and the
infected erythrocyte. These results correlate with P. falciparum
transcriptome data (5, 32) (PlasmoDB entry PFL1420w). Fur-
thermore, proteome surveys have indicated that the protein is
also present in all P. falciparum and P. berghei life cycle stages
analyzed (23, 25). The apparent discrepancy between the pres-
ence of the messenger and the presence of the protein might
be explained by differences in protein and mRNA stability and
turnover. In blood stage parasites, release of PMIF is most
likely episodic, coinciding with rupture of the infected eryth-
rocytes and release of merozoites. Recombinant His6-tagged
PMIF and huMIF elute at apparent molecular masses of 30
and 22 kDa in size exclusion chromatography, and these sizes
are both consistent with a dimeric form in solution. Until
FIG. 7. Parasite and reticulocyte densities in pbmif-ko-infected mice. The values are means and standard errors for asexual stage and
reticulocyte density during infections in experiment 2, obtained by using BALB/c mice (A.1 and A.2) and C57BL/6 mice (B.1 and B.2). For each
host strain, five infections were initiated with either wild-type parasites (WT) or one of two independently generated pbmif-ko lines (KO1 and
KO2). In both host strains the densities of circulating reticulocytes were significantly lower in infections initiated with wild-type parasites than in
infections initiated with pbmif-ko parasites (A.1 and B.1). In contrast, the densities of asexual parasites did not differ significantly in infections
initiated with wild-type parasites and infections initiated with pbmif-ko parasites (A.2 and B.2).
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recently, the oligomerization state of huMIF had been under
debate, with reports showing monomeric, dimeric, and trimeric
forms based on cross-linking experiments and dimeric forms
based on size exclusion chromatography analyses. A trimeric
form in solution was firmly established in sedimentation equi-
librium studies (reference 40 and references therein). Since
PMIF-His6 appeared to behave like huMIF-His6 in size exclu-
sion chromatography and huMIF-His6 appeared to behave like
untagged huMIF in previous work (37), the His6 tag does not
appear to affect oligomerization. However, a more in-depth
study is required to determine the exact oligomerization status
of PMIF in solution.
There have been conflicting reports about the relevance of
the C terminus of huMIF with regard to enzymatic activity (2,
36). In our assays, a C-terminal His6 tag did not appear to
influence enzymatic activity. Recombinant PMIF-His6 showed
tautomerase and oxidoreductase activities, although in both
assays the activities were 	20% of the recombinant huMIF-
His6 activities. It is surprising that PMIF-His6 retains oxi-
doreductase activity in the absence of the second cysteine of
the CXXC motif and with the low level of conservation of
surrounding sequences. However, given the low level of con-
servation, we cannot directly compare the PMIF and its oxi-
doreductase activity to the human C60S MIF mutant (which
exhibited only background activity compared to wild-type MIF
in the HED assay) and its activity. For example, the cysteine in
PMIF that would correspond to C57 in mammalian MIF is
shifted by one register in the alignment (Fig. 1A). Rather, the
remaining oxidoreductase activity in PMIF can be seen as an
intermediate between the activity of human C57S MIF (which
exhibits about 60% of the wild-type MIF activity in the HED
assay) and the activity of C60S MIF (29). However, we cannot
exclude the possibility that the N-terminal cysteine residues
may contribute to this effect by transferring protons from re-
duced glutathione to HED. It is also possible that the struc-
tural requirements for oxidoreductase activity are fulfilled in
the PMIF multimer.
Despite the relatively low enzymatic activity and low se-
quence similarity compared to huMIF, we found that recom-
binant PMIF-His6 and the huMIF-His6 control are equally
efficient in reducing AP-1 activation in HEK cells. The exact
structural requirements for Jab-1 binding and the inhibition of
Jab-1-mediated activation of AP-1 are currently unknown. Pre-
vious studies have implied that in huMIF, a structural rear-
rangement involving the oxidoreductase activity (involving
C60) is required for this activity (8, 28, 38). However, peptides
spanning the CXXC motif with either the wild-type or C57S/
C60S double point mutant sequence can compete for huMIF
binding to Jab-1 (27). In the absence of a strong oxidoreduc-
tase activity and the crucial C60 residue in PMIF, therefore,
structural differences may account for PMIF’s ability to inhibit
Jab-1 function. Alternatively, differences in protein uptake or
stability in HEK cells between PMIF and huMIF might explain
this effect.
PMIF is not essential for any phase of the Plasmodium life
cycle. Furthermore deletion of PbMIF did not consistently
influence standard virulence parameters, such as red blood cell
loss, weight loss, and parasite growth, in the early stages of a P.
berghei infection. However, infections in two host strains re-
vealed a clear and significant increase in reticulocyte produc-
tion in the early stages of pbmif-ko infection such that the
pbmif-ko-infected hosts had 1.5- to 4.5-fold more circulating
reticulocytes than wild-type-infected hosts. Accurately charac-
terizing the phenotypic effects of MIF expression is difficult
using these combinations of P. berghei and inbred mice due to
the rapid and lethal progression of the infections. Such studies
may be more informative if they are carried out with Plasmo-
dium chabaudi, which causes a chronic infection in inbred
mouse strains. These studies should rely on the P. chabaudi
genetic transformation technology that has been developed
recently (S. Reece and J. Thompson, unpublished data).
None of the studies on the host MIF response to Plasmo-
dium infection published thus far have taken the presence of
parasite-encoded MIF into account (1, 13, 14, 15, 34, 35).
Intriguingly, two of these studies clearly showed that MIF has
a role as a host-derived factor inhibiting erythropoiesis in the
context of P. chabaudi infection in BALB/c mice (34, 35). Our
results showing increased reticulocyte numbers in pbmif-ko
infections match well with these studies and indicate that par-
asite-encoded MIF might work in concert with host MIF to
suppress erythropoiesis in the context of a Plasmodium infec-
tion. Furthermore, McDevitt et al. observed a mild increase in
host survival when infection was carried out with MIF knock-
out mice. Therefore, it should be of interest to monitor the
course of infection of the pbmif-ko parasite in a MIF knockout
mouse strain. At this time it is unclear how this inhibitory effect
on reticulocyte numbers might benefit the parasite; since P.
berghei is a reticulocyte-preferring parasite, PbMIF appears to
act to reduce the preferred host blood cell pool for invasion.
However, suppression of erythropoiesis may lead to mainte-
nance of a lower level of parasitemia, which might contribute
to a longer-lasting infection. Thus, it is clear that further re-
search on the behavior of the pmif-ko parasites in the context
of chronic and also genetically diverse infections is required to
understand the action of PMIF.
Since MIF is a central regulator of the inflammatory re-
sponse in vertebrates (for a review, see reference 11), release
of a parasite homologue is likely to influence this response. It
seems counterintuitive that parasites produce a protein that
could both initiate a potentially lethal inflammatory immune
response and demonstrably reduce the population of red cells
preferred for asexual proliferation. However, huMIF has been
shown to be able to act upon both pro- and anti-inflammatory
pathways, depending on the context and concentration (28; for
a review, see reference 11). This raises the intriguing possibility
that parasites produce MIF homologues to subversively switch
the host immune response from a proinflammatory setting to
an anti-inflammatory setting, for instance by expressing an
excess amount of parasite MIF that competes with host MIF
for effector binding sites and so desensitizes host signaling for
the proinflammatory response. Preliminary data indeed show
that PMIF binds to CD74, which has been identified as a MIF
surface receptor (31), with higher affinity than huMIF binds
(unpublished observation). We are currently generating a
transgenic P. berghei parasite which overexpresses PbMIF in
the hope that further characterization of the role of PMIF in
an in vivo setting and further biochemical studies with recom-
binant PMIF will provide additional insights into the role of
this cytokine homologue in relation to the host response. Al-
ternatively, parasites may purposefully induce an inflammatory
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response, using the host immune system as a means to regulate
the population of competing parasites within hosts. Further
characterization of host responses to PMIF after short-term
exposure, as well as long-term exposure, is required to distin-
guish between these two possibilities. Finally, since parasite
MIF homologues are not limited to Plasmodium, the findings
presented in this study should have implications for the study
of host-parasite dynamics in other parasites.
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